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Abstract 
Background: Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease 
that primarily affects premature infants. Despite medical advances, mortality and 
morbidity from NEC is still unacceptably high. This is partly due to the lack of specific 
biomarkers and therapies for this disease. Availability of high-quality biological samples 
and the associated data from premature infants are key to advance our understanding 
of NEC, and for biomarker discovery and drug development. To that end, the NEC 
Society Biorepository was established with the goal of promoting studies in human 
infants through sharing specialized biospecimen and data procurement for NEC 
research. 
Objective: In this review, we will discuss the required infrastructure for biobanks, 
discuss the importance of informatics management, and emphasize the logistical 
requirements for sharing specimens. Finally, we will discuss the mechanism for how 
tissues and material will be shared between the institutions.   
Conclusion: We have developed a state-of-the-art biobank for human infants to 
advance the field of NEC research. With the NEC Society Biorepository, we seek to 
facilitate and accelerate the basic and translational studies on NEC to provide hope to 
the infants afflicted with NEC and their families. 
Study type: Review Article, level V 
Keywords: Biobank, samples, procurement, barcode, biomarker, biorepository 
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Introduction 
Purpose of the necrotizing enterocolitis (NEC) biorepository 
Necrotizing enterocolitis (NEC) is the most common gastrointestinal pathology 
associated with prematurity, and the mortality remains significant [1, 2]. Notably, there 
have been no new advances in diagnostic or therapeutics for NEC in several decades, 
and as such, the unacceptable clinical outcomes continue to be present. To advance 
the field of neonatal medicine, and NEC in particular, translational molecular-based 
studies are required which utilize biological samples from premature neonates. The 
availability of high quality neonatal biological samples plays a critical role in accelerating 
the outcomes of translational research studies and provides the foundation for 
personalized medicine. These neonatal biological samples are housed in biobanks, 
which are collections of samples collected for research purposes. In 2014, the NEC 
Society, a non-profit organization, was established with the primary goal of building a 
world without NEC through research collaborations and improving the broader 
knowledge base on the scope of the disease. In the first inaugural meeting in 2017, a 
focus group of researchers and clinicians was convened to consider the merits and 
challenges of establishing a national biorepository and registry. The group consensus 
was that a NEC biorepository is essential to advance the state of the science in the 
hopes to develop novel diagnostic approaches and identify therapeutic targets to 
prevent and/or treat the disease. This led to the launch of the NEC Society 
Biorepository [3] in 2018 to serve as an international resource that will provide an 
opportunity to facilitate collaborations between multiple centers and expand the 
available number of patients, biological samples and corresponding clinical data. In this 
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article, we will first describe the best practices for specimen procurement, we will then 
highlight our established infrastructure for the NEC biorepository, discuss the 
importance of informatics management, as well as emphasize the logistical 
requirements for sharing specimens, data and the ethical implications.  
 
Specimen Procurement and Best Practices  
The NEC Society Biorepository is a newly established biobank of multiple 
samples including blood, urine, stool, gastric aspirates, resected intestine and genomic 
DNA from infants with NEC, as well as from appropriate control patients such as those 
with atresia, ostomy closure, and volvulus. Procurement of the samples requires a 
trained team of individuals responsible for collecting specimens in an expedited manner 
with the goal to minimize the ischemic time for the tissue. Capabilities for 24-hour 
enrollment and sample acquisition are ideal for optimizing specimen integrity and 
quality.  
At our current NEC Biorepository sites, samples are picked up from the NICU at 
least twice per day and the timing of both collection by nursing as well as delivery to the 
lab for aliquoting are recorded. For blood and urine collection, samples should be 
processed and aliquoted immediately and cryopreserved preferably within 4 hours after 
collection. Data on the type of specimen, date and timing of collection relative to 
diagnosis of NEC should be included with the samples. For surgically resected intestinal 
specimens in particular, a procurement service for timely specimen retrieval and 
aliquoting is essential [4]. This procurement occurs via two different methods depending 
on the participating center. One approach is to have the specimen taken immediately 
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from the operating room to pathology, and the pathologist cuts several aliquots which 
could be picked up by research investigators for processing, aliquoting, and appropriate 
storage. The second method in hospital settings where there is not access to 24-hour 
pathology services to assist with cutting specimens is to utilize a research investigator 
on-call team, where laboratory members in pediatrics or surgery are called to collect 
and immediately process the tissues. This processing includes collecting a portion of 
each sample in an RNA stabilization reagent, a piece fixed in formalin for histologic 
assessment, and another piece placed in liquid nitrogen snap frozen for analysis at a 
later date. Importantly, we have learned throughout this process that the intestinal tissue 
cannot be placed in a refrigerator or freezer and must be processed expeditiously to 
maintain high-quality samples. 
For sample tracking purposes, a barcoding system with consideration of the 
specific sample location is required for efficient specimen retrieval. A sample storage 
log with the location, freeze/thaw records, and audit trails of sample acquisition as well 
as documentation of the restocking of any unused sample is necessary for biorepository 
quality control.  
 
Infrastructure 
Two main models of biobank networks exist; the federated biobank model where 
participating centers store their samples and maintain their inventory with capacity for 
sample sharing; and the centralized biobank model where samples are collected from 
participating sites and transferred to a central biobank for processing and storage [5]. 
Infrastructure vary based on the biobank mission, resource scope [6] and adequate 
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equipment, staffing, and facilities should be established according to the services to be 
provided, specimens collected, and researchers served.  
In general, requirements for biobanks include ample space with dedicated areas 
for receiving, processing, storing samples, and shipping if needed. Ideally, space should 
be located within an academic hospital, or close to neonatal intensive care units 
(NICUs) and operating rooms, to facilitate access to clinical samples, research support, 
and minimize the time of sample transfer. Storage equipment selection should be based 
on the size of the repository, the anticipated number of specimens to be stored, and the 
funding available. At a minimum, alarmed freezers (-80 degrees Celsius or lower), 
refrigerators, centrifuge, and computer equipment are required. Newer freezers and 
refrigerators provide automated sample entry and retrieval which are initially expensive 
but may reduce long term costs [7]. Liquid nitrogen or -150 degrees Celsius freezers are 
also recommended for optimal storage of some types of biological material. Where 
liquid nitrogen is used, daily use should be recorded, and adequate supply maintained. 
To minimize cost, resource sharing of autoclaves, wet/dry ice, and biological safety 
cabinets are preferable. Temperature monitoring systems and automated alarm 
systems should be in place to continuously monitor equipment and warn personnel 
when equipment failure occurs. In addition, visual inspection of equipment temperatures 
should be performed regularly, and charts recorded. Backup power sources should be 
set to activate automatically and should be routinely tested. Adequate backup storage 
and alternate cooling sources should be available in anticipation of possible equipment 
failure [8]. For ambient temperature storage, cabinets should be equipped with passive 
or active humidity controls to maintain biospecimens [9]. 
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Biospecimen Sharing 
Translating research from bench to bedside relies significantly on the availability 
of high quality and clinically annotated biospecimens [10]. Unfortunately, meeting the 
research needs in NEC will be unachievable by a single biobank due to additional and 
unique barriers compared to other disease-specific biobanks. These barriers include 
fewer NEC investigators, difficulty obtaining samples due to emergent operative 
decisions, and limitations in sample volumes [11, 12]. Therefore, developing NEC 
biobanking strategies that utilize multiple collection sites combined virtually as seen in 
the federated model or stored in a centralized biobank, will increase the number and 
types of specimens available for researchers. In the NEC Society Biorepository, 
samples are virtually combined by uploading the accompanying information into a 
shared database. Such models already exist for other disease-specific biorepositories 
as well and led to the establishment of networks at the international and national level 
[13-15]. The success of these networks exemplifies the tremendous power of teamwork 
in science and serves as a model for the future development of projects and enhanced 
collaboration. 
To identify sample availability and access associated clinical data, researchers 
utilize a NEC Society Biorepository specimen request tool online 
https://necsociety.org/2018/02/13/nec-society-research-collaborative-launches-nec-
biorepository-2/, which requires providing the appropriate IRB approval, funding source, 
and type of specimens or data requested. The researcher is then asked to submit a 1-2-
page proposal detailing the intent, background information, preliminary data if available, 
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and significance of the information requested. The NEC Society Biorepository 
leadership, composed of a pediatric surgeon, a neonatologist, and a patient-family 
representative, evaluates the requests to ensure the scientific validity of the research 
projects, regulatory adherence, and any potential conflicts of interest, then approves or 
rejects the request. Biospecimen distribution should be based on a defined priority and 
order of usage for investigators based on the quality of the research project, availability 
of specimens, and the appropriate controls. Currently, while the NEC Biorepository is in 
the sample acquisition phase of development, we ask that investigators interested in 
obtaining samples from our biobank, also join in the efforts of assisting with enrollment 
and procurement at their center. This will help build up the resources for other 
investigators and future studies.  
 
Biospecimen shipping and tracking 
The first step before initiation of biospecimen shipment should be determining the 
regulatory and physical requirements for proper shipping conditions [16, 17]. Shipments 
should conform to the appropriate governing regulations such as the International Air 
Transport Association (IATA) standards for air shipments [18]. Most international 
shipments require additional permits unique to certain countries and need customs 
clearance displayed on the outside of the package [19]. Shipment of cold or frozen 
material should be with sufficient and appropriate refrigerant, specifically using dry ice in 
an insulated container, enough to allow for at least a 24-hour delay in arrival time. For 
international shipments, three days’ worth of refrigerant is recommended in anticipation 
of possible delays in completing customs requirements. Shipments should be tracked 
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by both the shipper and recipient while in transit with an effective tracking system from 
the collection site through arrival. Components of tracking systems should include the 
use of unique identifiers or barcodes, specimen labels, and data inventory systems [20, 
21]. In addition, the inventory system should track the location of samples in storage, 
sample movements and status changes, specimen container type, volume or size, time 
and date of collection, temperature, as well as a preservative. Additional information 
stored in the inventory varies according to the biospecimens and their intended use but 
allows for digitally scanned documents to be included such as pathology reports, donor 
consent forms, and material transfer agreements if applicable.  
 
Informatics and data management 
One of the main obstacles to the progress of biomedical research is the lack of 
standardized, high-quality data associated with stored samples [5]. Therefore, the 
strategy for the NEC Society Biorepository has focused on establishing harmonized 
databases such as a Research Electronic Data Capture (REDCap) for clinical 
information and integration of the specimen metadata as well as into a database 
called Open Specimen. The objective being to link adequate data with tissue 
specimens that are visible to researchers, regardless of their geographical location [8]. 
The informatics systems at participating centers have the capabilities that allow: 1) 
inventory functions; 2) data collection and storage; and 3) the ability to query and 
exchange data between biobanks without compromising security and patient privacy 
[22]. The inventory system includes tracking of patient enrollment, consent 
documentation; biospecimen collection, processing, and dissemination; data security; 
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and management reporting. The informatics system stores a minimum set of clinical 
data annotated to the biospecimen. This minimum dataset was determined in 
consultation with the participating centers and is based on the needs of researchers, as 
well as overall feasibility and cost. A consensus was reached regarding the terminology 
used and classification of NEC to harmonize data among all of the participating centers. 
Interoperability to integrate both clinical and research data as well as distribute 
biospecimen resources is key to the exchange of data and biospecimens. This 
interoperability enables integration with local systems and authorized external systems 
where relevant data can be captured and shared securely. Most importantly, the 
informatics system storing patient identifiers and protected health information conforms 
to Health Insurance Portability and Accountability Act (HIPAA) or its equivalent and 
meets the criteria for National Institute of Standards and Technology (NIST) guidelines 
[23]. 
 
Ethical and legal aspects of biobanks  
Participating biobanks need to adhere to national human subjects’ regulations, 
privacy regulations and other relevant international, national, state and local laws. We 
acknowledge that a NEC diagnosis is often a traumatic experience for the parents of 
these fragile neonates. Accordingly, consent must be facilitated in an empathetic, 
responsive and empowering way. Parents should be provided with as much information 
as possible in an effort to help families better understand the value of research, what it 
means to participate, and their ability to help improve outcomes for babies and families 
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just like theirs. Parents should be viewed and valued as partners in care and in 
research. The following additional issues must be considered: 
- Informed Consent: Consent is obtained from parents or legal guardians of infants 
unless waived by an authorized human subjects/ethics committee with applicable 
laws or regulations [24]. Parents/guardian must be informed of potential genetic 
analysis on stored material and can opt-out or be excluded from the study. Under 
45 CFR 46, if the long-term future use of identified stored biospecimens is likely 
to constitute greater than minimal risk, biobanks should develop procedures for 
recontacting participants to obtain the consent of the now-adult participant. 
Informed consent should contain details on where the samples will be stored, 
and what information can be shared with other researchers. In certain instances, 
such as the procurement of deidentified intestinal tissue, the IRB may consider a 
waiver of consent if appropriate under 45 CFR 46.11(d). Specifically, for the NEC 
Biorepository, a waiver of consent to obtain deidentified resected intestinal tissue 
is approved by the IRB at Washington University School of Medicine in St. Louis 
if families are unavailable for consenting. In addition, investigators should be 
aware of other competing studies for which patients and families are eligible, and 
limit the approaches to families during emotionally sensitive times. Investigators 
could consider rotating which studies for which patients and families are 
approached, or design a common consent process for similar or related studies 
to limit the burden on families. 
- Privacy: Biobanks should follow well-documented procedures to protect the 
privacy and confidentiality of infants including assigning a unique code and 
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removing all identifying information from the specimens; securely storing 
specimens and data, and providing firewalls between the subject identity and the 
recipient investigator. 
- Access: Biobanks should develop policies governing information on specimen 
availability and sharing that is guided by general principles of scientific merit, 
research qualification, and ethical/legal considerations. 
- Material Transfer Agreement (MTA): An agreement with terms consistent with the 
NIH Data Sharing Policy [25] and other applicable sharing policies, should be 
used for specimen transfer between organizations. The MTA should include a 
clear description of the biospecimens, agreement to abide by appropriate laws, 
rules and regulations; acknowledgments of the recipients’ right to further 
distribute the biospecimens; and description of any expectations regarding the 
dissemination of research data [26]. 
 
Funding 
One of the significant challenges in establishing and maintaining a NEC biobank 
is securing financial support that can sustain its operations long term. Funding is 
typically required to cover costs for the emerging research needs, equipment 
maintenance, personnel salaries, website development, as well as clinical and sample 
metadata upkeep. Ideally, this will be in the form of funding from local 
academic/research institutions, extramural grants, philanthropic sources, industry, 
and/or fees for services also known as recharge. Maintaining and allowing service 
recharge will help cost recovery and will be fundamental in sustaining the long-term 
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operation of the biobank. Notably, the NEC Society Biorepository aims to foster 
significant collaborations in the field and thus does not currently charge for utilization of 
the banked specimens.  
 
Future Opportunities and Studies 
Biobanking offers several opportunities for collaborations across institutions 
nationally and internationally. Specifically, for NEC, these specimens provide 
opportunities for several potential areas of discovery including biomarker development 
and genetic susceptibility including newer techniques of genomic, metabolomic, 
transcriptomic and proteomic approaches, enhancing the field of personalized medicine 
to neonates. In conclusion, we have developed a state-of-the-art biobank for human 
infants to advance the field of NEC research. With the NEC Society Biorepository, we 
seek to facilitate and accelerate the basic and translational studies on NEC to provide 
hope to the infants afflicted with NEC and their families.   
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